These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 11091176)
1. Increased osteoblastic activity in myelomatosis. Wong KF; So CC; Chan JK Br J Haematol; 2000 Oct; 111(1):1. PubMed ID: 11091176 [No Abstract] [Full Text] [Related]
2. Increased osteoblastic activity in myelomatosis. Wong KF; So CC; Chan JK Br J Haematol; 2000 Jul; 110(1):1. PubMed ID: 10930973 [No Abstract] [Full Text] [Related]
3. Role of osteoblast suppression in multiple myeloma. Stewart JP; Shaughnessy JD J Cell Biochem; 2006 May; 98(1):1-13. PubMed ID: 16440324 [TBL] [Abstract][Full Text] [Related]
4. Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Silvestris F; Cafforio P; Calvani N; Dammacco F Br J Haematol; 2004 Aug; 126(4):475-86. PubMed ID: 15287939 [TBL] [Abstract][Full Text] [Related]
5. Plasma cells in myelomatosis. Clarke JA; Salsbury AJ Med Biol Illus; 1968 Jul; 18(3):165. PubMed ID: 5663684 [No Abstract] [Full Text] [Related]
6. Bone-resorbing cells in multiple myeloma: osteoclasts, myeloma cell polykaryons, or both? Silvestris F; Ciavarella S; De Matteo M; Tucci M; Dammacco F Oncologist; 2009 Mar; 14(3):264-75. PubMed ID: 19286760 [TBL] [Abstract][Full Text] [Related]
7. A case of myelomatous pleural effusion: an unusual onset of multiple myeloma. Martinez-Iribarren A; Fernandez-Prendes C Blood; 2020 Jan; 135(2):153. PubMed ID: 31917840 [No Abstract] [Full Text] [Related]
8. [Morphology and growth mechanism of myeloma cells]. Miwa A Nihon Rinsho; 2007 Dec; 65(12):2140-52. PubMed ID: 18069254 [No Abstract] [Full Text] [Related]
9. Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis. Bueno C; Lopes LF; Greaves M; Menendez P Exp Hematol; 2007 Oct; 35(10):1477-8. PubMed ID: 17681665 [No Abstract] [Full Text] [Related]
10. Picture in clinical hematology no. 37: case of multiple myeloma with multilobated nuclei plasma cell. Koiso H; Yokohama A; Tsukamoto N; Murakami H Rinsho Ketsueki; 2009 May; 50(5):337-8. PubMed ID: 19483391 [No Abstract] [Full Text] [Related]
11. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma. Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190 [TBL] [Abstract][Full Text] [Related]
12. Negative regulation of the osteoblast function in multiple myeloma through the repressor gene E4BP4 activated by malignant plasma cells. Silvestris F; Cafforio P; De Matteo M; Calvani N; Frassanito MA; Dammacco F Clin Cancer Res; 2008 Oct; 14(19):6081-91. PubMed ID: 18829486 [TBL] [Abstract][Full Text] [Related]
13. [The development of plasma cells in case of myelomatosis (author's transl)]. Bichel J; Jensen KB Folia Clin Int (Barc); 1975 Mar; 25(3):187-8. PubMed ID: 1140480 [No Abstract] [Full Text] [Related]
16. CD32-mediated suppression of plasma cells in patients with multiple myeloma. Ross B Haematologica; 2006 Jul; 91(7):869A. PubMed ID: 16818269 [No Abstract] [Full Text] [Related]